Pratteln, Switzerland, October 3, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the Company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA)
Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in.
Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in JAMA Neurology (https://jamanetwork.com/journals/jamaneurology/fullarticle/2795868?utm campaign=articlePDF&utm medium=articlePDFlink&utm source=articlePDF&utm content=jamaneurol.2022.2480)Safety
Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot